AtriCure [ATRC] vs Becton, Dickinson [BDX] Detailed Stock Comparison
AtriCure
NASDAQ
Loading...
Becton, Dickinson
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: AtriCure wins in 6 metrics, Becton, Dickinson wins in 12 metrics, with 0 ties. Becton, Dickinson appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | AtriCure | Becton, Dickinson | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -37.85 | 36.04 | AtriCure |
| Price-to-Book Ratio | 3.91 | 2.11 | Becton, Dickinson |
| Debt-to-Equity Ratio | 16.63 | 76.34 | AtriCure |
| PEG Ratio | -57.97 | 11.82 | AtriCure |
| EV/EBITDA | -126.17 | 12.20 | AtriCure |
| Profit Margin (TTM) | -7.27% | 7.18% | Becton, Dickinson |
| Operating Margin (TTM) | -4.55% | 16.01% | Becton, Dickinson |
| EBITDA Margin (TTM) | N/A | 16.01% | N/A |
| Return on Equity | -7.85% | 5.89% | Becton, Dickinson |
| Return on Assets (TTM) | -3.53% | 3.69% | Becton, Dickinson |
| Free Cash Flow (TTM) | $-11.26M | $3.07B | Becton, Dickinson |
| Dividend Yield | N/A | 1.80% | N/A |
| 1-Year Return | 68.91% | -17.97% | AtriCure |
| Price-to-Sales Ratio (TTM) | 3.63 | 2.55 | Becton, Dickinson |
| Enterprise Value | $1.77B | $68.00B | Becton, Dickinson |
| EV/Revenue Ratio | 3.55 | 3.26 | Becton, Dickinson |
| Gross Profit Margin (TTM) | 74.54% | 42.81% | AtriCure |
| Revenue per Share (TTM) | $11 | $72 | Becton, Dickinson |
| Earnings per Share (Diluted) | $-0.77 | $5.16 | Becton, Dickinson |
| Beta (Stock Volatility) | 1.62 | 0.22 | Becton, Dickinson |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
AtriCure vs Becton, Dickinson Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| AtriCure | -1.64% | 2.62% | 11.63% | 13.25% | -15.97% | 16.15% |
| Becton, Dickinson | 3.10% | 9.71% | 10.81% | 15.21% | -15.70% | -14.57% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| AtriCure | 68.91% | -32.05% | -12.16% | 33.48% | 417.89% | 151.03% |
| Becton, Dickinson | -17.97% | -26.61% | -23.17% | 33.78% | 179.52% | 265.18% |
Performance & Financial Health Analysis: AtriCure vs Becton, Dickinson
| Metric | ATRC | BDX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.82B | $53.31B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 994,040 | 2,491,688 |
| 90 Day Avg. Volume | 605,813 | 2,881,043 |
| Last Close | $35.31 | $193.50 |
| 52 Week Range | $20.20 - $43.11 | $163.33 - $251.99 |
| % from 52W High | -18.09% | -23.21% |
| All-Time High | $89.18 (Nov 01, 2021) | $287.32 (Jul 24, 2023) |
| % from All-Time High | -60.41% | -32.65% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.17% | 0.05% |
| Quarterly Earnings Growth | 0.17% | -0.43% |
| Financial Health | ||
| Profit Margin (TTM) | -0.07% | 0.07% |
| Operating Margin (TTM) | -0.05% | 0.16% |
| Return on Equity (TTM) | -0.08% | 0.06% |
| Debt to Equity (MRQ) | 16.63 | 76.34 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $9.35 | $88.07 |
| Cash per Share (MRQ) | $2.37 | $2.38 |
| Operating Cash Flow (TTM) | $36.43M | $3.30B |
| Levered Free Cash Flow (TTM) | $1.65M | $3.50B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.80% |
| Last 12-Month Dividend | N/A | $3.03 |
Valuation & Enterprise Metrics Analysis: AtriCure vs Becton, Dickinson
| Metric | ATRC | BDX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -37.85 | 36.04 |
| Forward P/E | -57.97 | 11.82 |
| PEG Ratio | -57.97 | 11.82 |
| Price to Sales (TTM) | 3.63 | 2.55 |
| Price to Book (MRQ) | 3.91 | 2.11 |
| Market Capitalization | ||
| Market Capitalization | $1.82B | $53.31B |
| Enterprise Value | $1.77B | $68.00B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.55 | 3.26 |
| Enterprise to EBITDA | -126.17 | 12.20 |
| Risk & Other Metrics | ||
| Beta | 1.62 | 0.22 |
| Book Value per Share (MRQ) | $9.35 | $88.07 |
Financial Statements Comparison: AtriCure vs Becton, Dickinson
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ATRC | BDX |
|---|---|---|
| Revenue/Sales | $136.14M | $5.27B |
| Cost of Goods Sold | $34.66M | $3.02B |
| Gross Profit | $101.48M | $2.26B |
| Research & Development | $29.28M | $302.00M |
| Operating Income (EBIT) | $-6.19M | $637.00M |
| EBITDA | $732,000 | $1.21B |
| Pre-Tax Income | $-5.93M | $363.00M |
| Income Tax | $261,000 | $55.00M |
| Net Income (Profit) | $-6.19M | $308.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ATRC | BDX |
|---|---|---|
| Cash & Equivalents | $99.89M | $667.00M |
| Total Current Assets | $251.48M | $8.67B |
| Total Current Liabilities | $61.22M | $7.69B |
| Long-Term Debt | $74.57M | $17.67B |
| Total Shareholders Equity | $454.62M | $25.24B |
| Retained Earnings | $-408.50M | $16.15B |
| Property, Plant & Equipment | $48.21M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ATRC | BDX |
|---|---|---|
| Operating Cash Flow | $1.54M | $941.00M |
| Capital Expenditures | $-2.18M | N/A |
| Free Cash Flow | $-13.21M | $35.00M |
| Debt Repayment | $-287,000 | $-1.00M |
| Common Stock Repurchase | $-10.17M | $0 |
Short Interest & Institutional Ownership Analysis
| Metric | ATRC | BDX |
|---|---|---|
| Shares Short | 1.52M | 4.69M |
| Short Ratio | 3.74 | 1.49 |
| Short % of Float | 0.03% | 0.02% |
| Average Daily Volume (10 Day) | 994,040 | 2,491,688 |
| Average Daily Volume (90 Day) | 605,813 | 2,881,043 |
| Shares Outstanding | 48.87M | 289.10M |
| Float Shares | 47.92M | 285.93M |
| % Held by Insiders | 0.03% | 0.01% |
| % Held by Institutions | 1.02% | 0.93% |
Dividend Analysis & Yield Comparison: AtriCure vs Becton, Dickinson
| Metric | ATRC | BDX |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.03 |
| Last 12-Month Dividend Yield | N/A | 1.80% |
| 3-Year Avg Annual Dividend | N/A | $3.16 |
| 3-Year Avg Dividend Yield | N/A | 0.40% |
| 3-Year Total Dividends | N/A | $9.48 |
| Ex-Dividend Date | N/A | Mar 10, 2025 |